Rituximab - a game changer

In our latest podcast Dr Rob Lown, Consultant Haematologist at University Hospital Southampton talks to Lymphoma Action’s Anne Hook about the monoclonal antibody rituximab. 

Dr Lown explains what rituximab is and how it works to treat lymphoma, both as part of a chemotherapy regimen and as maintenance therapy. Dr Lown describes why rituximab was considered a ‘game changer’ in the treatment of B-cell lymphomas, and who may be given it as part of their treatment. 

Side effects of rituximab, the challenges of long-term treatment, biosimilars and newer antibodies such as Obinutuzumab are also discussed.